AusperBio is a technology company.
AusperBio is a Clinical Stage Company, Currently Focusing on HBV Cure.
AusperBio has raised $223.0M across 4 funding rounds.
AusperBio has raised $223.0M in total across 4 funding rounds.
AusperBio is a Phase II clinical-stage biopharmaceutical company focused on developing innovative therapies to cure chronic hepatitis B virus (HBV) infection and advancing oligonucleotide therapeutics. Their proprietary Med-Oligo™ antisense oligonucleotide (ASO) platform, combined with targeted delivery technologies, enables them to address a broad spectrum of diseases including viral infections, metabolic disorders, genetic conditions, and immune diseases. AusperBio’s work aims to transform patient outcomes by unlocking the therapeutic potential of ASO technology[1][2][4].
The company primarily serves patients suffering from chronic HBV and other serious diseases that currently lack effective treatments. By targeting the root causes at the genetic and molecular level, AusperBio addresses the unmet medical need for curative therapies in these areas. Their progression into Phase II clinical trials indicates growing momentum and validation of their approach within the biopharmaceutical landscape[1][4].
AusperBio was founded by a team of experts in biotechnology and molecular medicine, motivated by the urgent need for curative treatments for chronic HBV and other challenging diseases. The idea emerged from advances in oligonucleotide therapeutics and the recognition that targeted delivery was a critical barrier to clinical success. Early development focused on refining their Med-Oligo™ ASO platform to enhance efficacy and safety, leading to promising preclinical results and advancement into clinical trials. This evolution reflects a strategic focus on leveraging cutting-edge science to address significant global health challenges[1][2].
AusperBio operates at the intersection of biotechnology innovation and precision medicine, riding the trend of oligonucleotide therapeutics as a transformative modality for previously intractable diseases. The timing is critical as advances in molecular biology, delivery technologies, and regulatory acceptance converge to enable clinical success for ASO drugs. Market forces such as the global burden of chronic viral infections and genetic diseases create strong demand for novel curative therapies. AusperBio’s work contributes to expanding the therapeutic toolbox and influences the broader ecosystem by validating ASO platforms and encouraging investment in oligonucleotide-based drug development[1][2][4].
Looking ahead, AusperBio is poised to advance its clinical pipeline further, potentially expanding indications and refining its delivery technologies. Trends such as personalized medicine, gene-targeted therapies, and increasing regulatory support for nucleic acid drugs will shape their trajectory. As they progress, their influence may grow by setting new standards for ASO therapeutic development and demonstrating curative potential in chronic viral diseases. This positions AusperBio as a key player in the evolving landscape of biopharmaceutical innovation focused on genetic and molecular precision therapies[1][2].
AusperBio has raised $223.0M in total across 4 funding rounds.
AusperBio's investors include 01 Advisors, Abstract Ventures, Addition, B8, Bessemer Venture Partners, General Catalyst, Qiming Venture Partners, Redpoint Ventures, South Park Commons, Y Combinator.
AusperBio has raised $223.0M across 4 funding rounds. Most recently, it raised $63.0M Series B in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $63.0M Series B | 01 Advisors, Abstract Ventures, Addition, B8, Bessemer Venture Partners, General Catalyst, Qiming Venture Partners, Redpoint Ventures, South Park Commons, Y Combinator | |
| May 1, 2025 | $50.0M Series B | 01 Advisors, Abstract Ventures, Addition, B8, Bessemer Venture Partners, General Catalyst, Qiming Venture Partners, Redpoint Ventures, South Park Commons, Y Combinator | |
| Dec 1, 2024 | $73.0M Series B | 01 Advisors, Abstract Ventures, Addition, B8, Bessemer Venture Partners, General Catalyst, Qiming Venture Partners, Redpoint Ventures, South Park Commons, Y Combinator | |
| Jul 1, 2024 | $37.0M Series A | 01 Advisors, Abstract Ventures, Addition, B8, Bessemer Venture Partners, General Catalyst, Qiming Venture Partners, Redpoint Ventures, South Park Commons, Y Combinator |